MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 432-436

  Geisler, John P ^a   Geisler, Hans E ^a   Miller, Greg A ^c   Wiemann, Michael C ^b   Zhou, Zhen ^b   Crabtree, William ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Vincent Hospitals and Health Services   (United States)

^c Lab Diagn and Analyt Cytometry   (United States)

Author keywords

Endometrial carcinoma; MIB 1; Proliferation index; Survival

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ANTIBODY DETECTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER;

EID: 0032805760     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5615     Document Type: Article

References (43)

1. Nielsen A L, Nyholm H C, Engel P. Expression of MIB-1 (paraffin Ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type. Int J Gynecol Pathol. 13:1994;37-44.
2. Geisler J P, Weimann M C, Zhen Z, Miller G A, Geisler H E. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol Oncol. 61:1996;373-377.
3. Whang J D, Lee J H. Molecular genetics of gynecologic cancer. J Kor Med Sci. 12:1997;383-389.
4. Greven K M, Corn B W. Endometrial cancer. Curr Prob Cancer. 21:1997;65-127.
5. Evans M P, Podratz K C. Endometrial neoplasia: Prognostic significance of ploidy status. Clin Obstet Gynecol. 39:1996;696-706.
6. Orr J W, Orr P F, Taylor P T. Surgical staging endometrial cancer. Clin Obstet Gynecol. 39:1996;656-668.
7. Berchuck A. Biomarkers in the endometrium. J Cell Biochem. 23s:1995;174-178.
8. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg S G, Garrett C T. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 54:1994;4667-4670.
9. Yu C C, Wilkinson N, Brito M J, Buckley C H, Fox H, Levison D A. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology. 23:1993;367-371.
10. Nielsen A L, Nyholm H C. Endometrial adenocarcinoma of endometroid subtype with squamous differentiation: An immunohistochemical study of MIB-1 (ki-67 paraffin), cathepsin D, and C-erbB-2 protein. Int J Gynecol Pathol. 14:1995;230-234.
11. King S A, Adas A, Livolsi V A, Takahashi H, Behbakht K, McGovern P, Benjamin I, Rubin S C, Boyd J. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 75:1995;2700-2705.
12. Jeyarajah A, Oram D, Jacobs I. Molecular events in endometrial carcinogenesis. Int J Gynecol Cancer. 6:1996;425-438.
13. Key G, Becker M H, Baron B, Duchrow M, Schleter C, Flad H D, Gerdes J. New Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest. 68:1993;629-636.
14. Kerns B JM, Jordan P A, Faerman L L, Berchuck A, Bast R C, Layfield L J. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 101:1994;192-197.
15. Geisler J P, Wiemann M C, Miller G A, Zhou Z, Geisler H E. Change in MIB-1 staining between primary and recurrent epithelial ovarian cancer. Eur J Gynaecol Oncol. 16:1995;343-345.
16. Geisler J P, Zhou Z, Miller G A, Wiemann M C, Geisler H E. MIB-1: A predictor of survival in patients with ovarian carcinoma. Int J Gynecol Cancer. 8:1998;392-396.
17. Geisler, J, P, Geisler, H, E, Miller, G, A, Wiemann, M, C, Zhou, Z, Tammela, J, Markers of proliferation as prognostic indicators in epithelial ovarian carcinoma, CME J Gynecol Oncol, 3: in press.
18. Garzetti G G, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G, Biagnin G. Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in serous ovarian tumors: Index of proliferation activity with prognostic significance. Gynecol Oncol. 56:1995;169-174.
19. Cheung A N, Ngan H Y, Collins R J, Wong Y L. Assessment of cell proliferation in hydatidiform mole using monoclonal antibody MIB-1 to Ki-67 antigen. J Clin Pathol. 47:1994;601-604.
20. Layfield L J, Saria E A, Berchuck A, Dodge R K, Thompson J K, Conlon D H, Kerns B JM. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol. 66:1997;230-237.
21. Viale G, Maisonneuve P, Bonoldi E, Di Bacco A, Bevilacqua P, Panizzoni G A, Radaelli U, Gasparini. The combined evaluation of p53 accumulation and Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol. 8:1997;469-476.
22. Goff B GA, Muntz H G, Greer B E, Tamimi H K, Gown A M. Oncogene expression: Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 92:1998;88-93.
23. Anttila M, Kosma V M, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjanen K. Clinical significance of a-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol. 16:1998;2591-2600.
24. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;8-31.
25. DiSaia P J, Creasman W T. Adenocarcinoma of the uterus, in Clinical Gynecologic Oncology. 1993;Mosby Year Book, St. Louis. p. 156-193.
26. Creasman W T, Rutledge F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 110:1972;773-781.
27. Harouny V R, Sutton G P, Clark S A, Geisler H E, Stehman F B, Ehrlich C E. The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol. 723:1988;394-398.
28. Hanson M B, Van Nagell J R, Powell D E, Donaldson E S, Gallion H, Merhige M, Pavlik E J. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 55:1985;1753-1757.
29. Geisinger K R, Homesley H D, Morgan T M, Kute T E, Marshall R B. Endometrial carcinoma: A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid status. Cancer. 58:1986;1518-1525.
30. Iversen O E. Flow cytometric deoxyribonucleic acid index: A prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 155:1986;770-776.
31. Britton L C, Wilson T O, Gaffey T A, Cha S S, Wieand H S, Podratz K C. DNA ploidy in endometrial carcinoma: Major objective prognostic factor. Mayo Clin Proc. 65:1990;643-650.
32. Newbury R, Schuerch C, Goodspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol. 76:1990;251-257.
33. Moberger B, Auer G, Forsslund G, Moberger G. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry. 5:1984;430-436.
34. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer. 4:1994;94-100.
35. Geisler J P, Zhou Z, Miller G A, Wiemann M C, Geisler H E. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol. 61:1996;245-248.
36. Geisler J P, Zhou Z, Miller G A, Wiemann M C, Geisler H E. Markov texture parameters as prognostic indicators in endometrial cancer. Gynecol Oncol. 62:1996;174-180.
37. Berchuck A, Kohler M F, Marks J R, Wiseman R, Boyd J, Bast R C. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 170:1994;246-252.
38. Baak J PA, Kurver P HJ, Overdiep S H, Delemarre J FM, Boon M E, Lindeman J, Diegenbach P C. Quantitative, microscopical, computer-aided diagnosis of endometrial hyperplasia or carcinoma in individual patients. Histopathology. 5:1981;689-695.
39. Geisler J P, Geisler H E, Tammela J, Miller G A, Wiemann M C, Zhou Z. A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol. 72:1999;347-350.
40. McCormick D, Chong H, Hobbs C, Datta C, Hall P A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with monoclonal antibody MIB-1. Histopathology. 22:1993;355-360.
41. McCormick D, Yu C, Hobbs C, Hall P A. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology. 22:1993;543-547.
42. Veronese S M. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res. 15:1995;2717-2722.
43. Salvesen H B, Iversen O E, Akslen L A. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol. 17:1999;1382-1390.